Single photon emission computed tomography/computed tomography in the evaluation of neuroendocrine tumours: A review of the literature

Nuclear Medicine Communications

Volumn 34, Issue 2, 2013, Pages 98-107

  Lu, Suat Jin ^a,d   Gnanasegaran, Gopinath ^a   Buscombe, John ^c   Navalkissoor, Shaunak ^b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

^d NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

111In pentetreotide; 123I MIBG; 131I MIBG therapy; 18F DOPA; 68Ga DOTA TATE; metaiodobenzylguanidine scintigraphy; peptide receptor radionuclide therapy; positron emission tomography computed tomography; somatostatin receptor scintigraphy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ANGIOPEPTIN; CHROMOGRANIN A; DIHYDROXYPHENYLALANINE F 18; DOPAMINE F 18; DOTA LANREOTIDE IN 111; DOTATATE GA 68; HYDROXYTRYPTOPHAN C 11; OCTREOTIDE; PENTETREOTIDE; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

CANCER GRADING; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DOSIMETRY; DRUG RECEPTOR BINDING; ECHOGRAPHY; HUMAN; MITOSIS; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PROTEIN EXPRESSION; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR LOCALIZATION;

3-IODOBENZYLGUANIDINE; HUMANS; IODINE RADIOISOTOPES; NEUROENDOCRINE TUMORS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; SOMATOSTATIN;

EID: 84871621889     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32835bd59d     Document Type: Review

References (53)

1. Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 2001; 92:2204-2210.
2. Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology 2004; 80 (Suppl 1):3-7.
3. Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 1987; 5:1502-1522.
4. Gilligan CJ, Lawton GP, Tang LH, West AB, Modlin IM. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol 1995; 90:338-352.
5. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9:61-72.
6. Bombardieri E, Coliva A, Maccauro M, Seregni E, Orunesu E, Chiti A, et al. Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals. Q J Nucl Med Mol Imaging 2010; 54:3-15.
7. Gnanasegaran G, O'Doherty MJ. Imaging neuroendocrine tumours with radionuclide techniques. Minerva Endocrinol 2008; 33:105-126.
8. Jensen RT. Endocrine tumors of the gastrointestinal tract and pancreas. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL, et al., editors. Harrison's principles of internal medicine. 16th ed. New York: McGraw-Hill; 2005.
9. Klöppel G, Rindi G, Anlauf M, Perren A, Komminoth P. Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch 2007; 451 (Suppl 1):S9-S27.
10. Solcia E, Klöppel G, Sobin LH, in collaboration with 9 pathologists from 4 countries. Histological typing of endocrine tumours. WHO international histological classification of tumours. 2nd ed. Berlin: Springer; 2000.
11. Ansari A, Meeran K, Bloom SR. Classification of neuroendocrine tumors. In: Hay ID, Wass JAH, editors. Clinical endocrine oncology. 2nd ed. Massachusetts: Wiley-Blackwell; 2008.
12. Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449:395-401.
13. Bosman F, Carneiro F, Hruban R, Theise NWHO classification of tumours of the digestive system. Lyon, France: IARC Press; 2010.
14. Hicks RJ. Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy. Cancer Imaging 2010; 10 (Spec no A): S83-S91.
15. Arnold R, Simon B, Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion 2000; 62 (Suppl 1): 84-91.
16. Maecke HR, Behe M. New octreotide derivatives labeled with technetium-99m [Abstract]. J Nucl Med 1996; 37:1144.
17. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20:716-731.
18. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006; 36:228-247.
19. Lebtahi R, Cadiot G, Sarda L, Daou D, Faraggi M, Petegnief Y, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997; 38:853-858.
20. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 1996; 125:26-34.
21. Chiti A, Fanti S, Savelli G, Romeo A, Bellanova B, Rodari M, et al. Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-enteropancreatic tumours. Eur J Nucl Med 1998; 25:1396-1403.
22. Shi W, Johnston CF, Buchanan KD, Ferguson WR, Laird JD, Crothers JG, et al. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging. QJM 1998; 91:295-301.
23. De Kerviler E, Cadiot G, Lebtahi R, Faraggi M, Le Guludec D, Mignon M. Somatostatin receptor scintigraphy in forty-eight patients with the Zollinger-Ellison syndrome. GRESZE: Groupe d'Etude du Syndrome de Zollinger-Ellison. Eur J Nucl Med 1994; 21:1191-1197.
24. Termanini B, Gibril F, Reynolds JC, Doppman JL, Chen CC, Stewart CA, et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997; 112:335-347.
25. Zimmer T, Stölzel U, Bäder M, Koppenhagen K, Hamm B, Buhr H, et al. Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut 1996; 39:562-568.
26. Cadiot G, Lebtahi R, Sarda L, Bonnaud G, Marmuse JP, Vissuzaine C, et al. Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Groupe D'etude Du Syndrome De Zollinger-Ellison. Gastroenterology 1996; 111:845-854.
27. Alexander HR, Fraker DL, Norton JA, Bartlett DL, Tio L, Benjamin SB, et al. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg 1998; 228:228-238.
28. Mariani G, Bruselli L, Kuwert T, Kim EE, Flotats A, Israel O, et al. A review on the clinical uses of SPECT/CT. Eur J Nucl Med Mol Imaging 2010; 37:1959-1985.
29. Ricke J, Klose KJ. Imaging procedures in neuroendocrine tumours. Digestion 2000; 62 (Suppl 1):39-44.
30. Krenning EP, Kwekkeboom DJ, Reubi JC. Peptide receptor scintigraphy in oncology. Peptide receptor scintigraphy in oncology. In: Murray IPC, Ell PJ, editors. Nuclear medicine in clinical diagnosis and treatment. Edinburgh: Churchill Livingstone; 1998. pp. 859-870.
31. Krausz Y, Keidar Z, Kogan I, Even-Sapir E, Bar-Shalom R, Engel A, et al. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours. Clin Endocrinol (Oxf) 2003; 59:565-573.
32. Perri M, Erba P, Volterrani D, Lazzeri E, Boni G, Grosso M, et al. Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors. Q J Nucl Med Mol Imaging 2008; 52:323-333.
33. Castaldi P, Rufini V, Treglia G, Bruno I, Perotti G, Stifano G, et al. Impact of 111In-DTPA-octreotide SPECT/CT fusion images in the management of neuroendocrine tumours. Radiol Med 2008; 113:1056-1067.
34. Wong KK, Cahill JM, Frey KA, Avram AM. Incremental value of 111-In pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors. Acad Radiol 2010; 17:291-297.
35. Hillel PG, van Beek EJ, Taylor C, Lorenz E, Bax ND, Prakash V, et al. The clinical impact of a combined gamma camera/CT imaging system on somatostatin receptor imaging of neuroendocrine tumours. Clin Radiol 2006; 61:579-587.
36. Pé rault C, Schvartz C, Wampach H, Liehn JC, Delisle MJ. Thoracic and abdominal SPECT-CT image fusion without external markers in endocrine carcinomas. The Group of Thyroid Tumoral Pathology of Champagne-Ardenne. J Nucl Med 1997; 38:1234-1242.
37. Hedlund E, Karlsson JE, Starck SA. Automatic and manual image fusion of In-pentetreotide SPECTand diagnostic CT in neuroendocrine tumor imaging-an evaluation. J Med Phys 2010; 35:223-228.
38. Amthauer H, Denecke T, Rohlfing T, Ruf J, Böhmig M, Gutberlet M, et al. Value of image fusion using single photon emission computed tomography with integrated low dose computed tomography in comparison with a retrospective voxel-based method in neuroendocrine tumours. Eur Radiol 2005; 15:1456-1462.
39. Wong KK,Wynn EA, Myles J, Ackermann RJ, Frey KA, Avram AM. Comparison of single time-point [111-In] pentetreotide SPECT/CT with dual time-point imaging of neuroendocrine tumors. Clin Nucl Med 2011; 36:25-31.
40. Gabriel M, Hausler F, Bale R, Moncayo R, Decristoforo C, Kovacs P, et al. Image fusion analysis of (99m)Tc-HYNIC-Tyr(3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours. Eur J Nucl Med Mol Imaging 2005; 32:1440-1551.
41. Rozovsky K, Koplewitz BZ, Krausz Y, Revel-Vilk S, Weintraub M, Chisin R, et al. Added value of SPECT/CT for correlation of MIBG scintigraphy and diagnostic CT in neuroblastoma and pheochromocytoma. Am J Roentgenol 2008; 190:1085-1090.
42. Meyer-Rochow GY, Schembri GP, Benn DE, Sywak MS, Delbridge LW, Robinson BG, et al. The utility of metaiodobenzylguanidine single photon emission computed tomography/computed tomography (MIBG SPECT/CT) for the diagnosis of pheochromocytoma. Ann Surg Oncol 2010; 17:392-400.
43. Fukuoka M, Taki J, Mochizuki T, Kinuya S. Comparison of diagnostic value of I-123 MIBG and high-dose I-131 MIBG scintigraphy including incremental value of SPECT/CT over planar image in patients with malignant pheochromocytoma/ paraganglioma and neuroblastoma. Clin Nucl Med 2011; 36:1-7.
44. Ozer S, Dobrozemsky G, Kienast O, Beheshti M, Becherer A, Niederle B, et al. Value of combined XCT/SPECT technology for avoiding false positive planar (123)I-MIBG scintigraphy. Nuklearmedizin 2004; 43:164-170.
45. Kizu H, Takayama T, Tsushima H, Noguchi A, Nakajima K, Onoguchi M, et al. Localization of metastases from malignant pheochromocytoma in patients undergoing 131I-MIBG therapy with manually fused 123I-MIBG SPECT and CT images. J Nucl Med Technol 2008; 36:186-188.
46. Bhatia KS, Ismail MM, Sahdev A, Rockall AG, Hogarth K, Canizales A, et al. 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxf) 2008; 69:181-188.
47. Maurea S, Cuocolo A, Reynolds JC, Neumann RD, Salvatore M. Diagnostic imaging in patients with paragangliomas. Computed tomography, magnetic resonance and MIBG scintigraphy comparison. Q J Nucl Med 1996; 40:365-371.
48. Gao YC, Lu HK, Luo QY, Chen LB, Ding Y, Zhu RS. Comparison of free plasma metanephrines enzyme immunoassay with (131)I-MIBG scan in diagnosis of pheochromocytoma. Clin Exp Med 2008; 8:87-91.
49. Forrer F, Mueller-Brand J, Maecke H. Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2005; 32:511-512.
50. Barone R, Walrand S, Konijnenberg M, Valkema R, Kvols LK, Krenning EP, et al. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide. Nucl Med Commun 2008; 29:283-290.
51. Ambrosini V, Tomassetti P, Franchi R, Fanti S. Imaging of NETs with PET radiopharmaceuticals. Q J Nucl Med Mol Imaging 2010; 54:16-23.
52. Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med 2010; 51:875-882.
53. Rufini V, Treglia G, Castaldi P, Perotti G, Calcagni ML, Corsello SM, et al. Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma. Nucl Med Commun 2011; 32:575-582.